Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Potential of RAS inhibition to improve metabolic bone disorders.

Gebru Y, Diao TY, Pan H, Mukwaya E, Zhang Y.

Biomed Res Int. 2013;2013:932691. doi: 10.1155/2013/932691. Epub 2013 Jul 22. Review.

2.

Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.

Diao TY, Pan H, Gu SS, Chen X, Zhang FY, Wong MS, Zhang Y.

J Bone Miner Metab. 2014 May;32(3):261-70. doi: 10.1007/s00774-013-0500-7. Epub 2013 Aug 10.

PMID:
23934056
3.

Potential effect of angiotensin II receptor blockade in adipose tissue and bone.

Nakagami H, Osako MK, Morishita R.

Curr Pharm Des. 2013;19(17):3049-53. Review.

PMID:
23176218
4.

To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.

St Peter WL, Odum LE, Whaley-Connell AT.

Pharmacotherapy. 2013 May;33(5):496-514. doi: 10.1002/phar.1232. Epub 2013 Apr 9. Review.

PMID:
23576066
5.
8.
9.
10.

[Activation of osteoclasts by RAAS and strategy of target therapy on bone metabolic diseases].

Shimizu H, Nakagami H, Morishita R.

Nihon Rinsho. 2012 Sep;70(9):1524-9. Japanese.

PMID:
23012798
11.

Dual RAS therapy not on target, but fully alive.

Lambers Heerspink HJ, de Zeeuw D.

Nephron Clin Pract. 2010;116(2):c137-42. doi: 10.1159/000315882. Epub 2010 Jun 1. Review.

12.

Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.

Kubota M, Shimizu M, Sakai H, Yasuda Y, Ohno T, Kochi T, Tsurumi H, Tanaka T, Moriwaki H.

Biochem Biophys Res Commun. 2011 Jun 24;410(1):108-13. doi: 10.1016/j.bbrc.2011.05.115. Epub 2011 May 26.

PMID:
21640075
13.

Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems.

Lee MA, Paul M, Böhm M, Ganten D.

Am J Cardiol. 1992 Oct 8;70(10):12C-19C. Review.

PMID:
1414888
14.
15.

Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition.

Sullivan JC.

Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1220-6. doi: 10.1152/ajpregu.00864.2007. Epub 2008 Feb 20. Review.

16.

Rationale for combining blockers of the renin-angiotensin system.

Azizi M, Wuerzner G.

Semin Nephrol. 2007 Sep;27(5):544-54. Review.

PMID:
17868792
17.

Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.

Heerspink HJ.

Adv Chronic Kidney Dis. 2011 Jul;18(4):290-9. doi: 10.1053/j.ackd.2011.04.001. Review.

PMID:
21782135
18.

Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.

Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ.

Diabet Med. 2011 Oct;28(10):1182-7. doi: 10.1111/j.1464-5491.2011.03341.x.

PMID:
21627686
19.

Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.

Scott BB, McGeehan GM, Harrison RK.

Curr Protein Pept Sci. 2006 Jun;7(3):241-54. Review.

PMID:
16787263
20.

Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study.

Bajaj RR, Wald R, Hackam DG, Gomes T, Perl J, Juurlink DN, Manno M, Garg AX, Kitchlu A, Mamdani MM, Yan AT.

Arch Intern Med. 2012 Apr 9;172(7):591-3. doi: 10.1001/archinternmed.2012.139. No abstract available. Erratum in: Arch Intern Med. 2012 Jun 25;172(12):908.

PMID:
22493468
Items per page

Supplemental Content

Write to the Help Desk